Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARE-PVD: Rosuvastatin/Ezetimibe vs Rosuvastatin in PAD
NCT06231966Recruiting
- Sponsor
- Yonsei University
- Start
- Apr 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ezetimibe in peripheral artery disease (PAD) and polyvascular disease (2 arms), sponsored by Yonsei University. Primary endpoint: Composite of Major cardiovascular event or major adverse limb event at 3 years. Started Apr 2024; status: recruiting.
02
Drugs
ezetimibe
03
Conditions
peripheral artery disease (PAD)polyvascular disease
Beyond the preview
Go deeper on NCT06231966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06231966.